Diagnosis of acute MI Pharmacologic therapy* Immediate angiography PTCAPTCA Other Rx *Antithrombin agents, antiplatelet agents, and fibrinolytic agents.

Slides:

Advertisements

Similar presentations

Presented by: Fahim H. Jafary, M.D., F.A.C.C. Associate Professor of Medicine Aga Khan University Hospital, Karachi March 14, 2008 Primary Percutaneous.

Advertisements

Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.

PACT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.

Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon.

A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.

Primary PCI Treatment of choice for Acute MI.

Time Is Myocardium and the Wavefront of Necrosis CM Gibson 2002.

Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.

The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Pathophysiology of Combination Therapy in AMI *Gibson et al. J Am Coll Cardiol. 1995;25: Gibson et al. Circulation. 2001;103: Combination.

Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.

BME 301 Lecture Seventeen. Review of Last Time Burden of heart disease Cardiovascular system How do heart attacks happen?

ACS and Thrombosis in the Emergency Setting

Prehospital Fibrinolysis with Double Antiplatelet Therapy in Acute ST-Elevation Myocardial Infarction: The Clarity Ambulance Substudy Prehospital Fibrinolysis.

Enhancement of thrombolysis in AMI is an unmet clinical need Increase the rate of reperfusion without increasing bleeding Reduce the time to complete reperfusion.

Background Fibrinolytic Rx in STEMI is limited by inadequate reperfusion and/or reocclusion in ~25% of pts. An occluded infarct-related artery is associated.

Primary Angioplasty and Hemodynamic Support in Cardiogenic Shock Department of Internal Medicine, College of Medicine, Yonsei University Hyuck Moon Kwon,

Incidence of Acute Coronary Syndromes (ACS): Statistics From Various Studies 1.4 million hospitalizations each year for ACS 944,000 hospitalizations for.

Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

The 90 Minute Wall: 60% Rates of TIMI Grade 3 Flow % TIMI 3 Flow.

The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.

TIMI 10A Protocol Design TNK- tPA Bolus ASA + IV Heparin (APTT 55-85) Follow-up Hosp. Discharge to 30 days Pt. with Acute MI < 12h End Points: Pharmacokinetics.

1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.

Nick Alp Milton Keynes Hospital NHS FT Oxford Radcliffe NHS Trust Bleeding risks in the major trials – It does matter.

ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.

The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.

NSTE Acute Coronary Syndromes

VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise,

SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Randomized Early versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) Mauro Maioli, MD, Francesco.

Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.

Thrombectomy in Acute Stroke

Study Design AMI <12 hours, any age, cardiogenic shock excluded

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Giuseppe Biondi Zoccai University of Turin, Turin, Italy

Section 5: Intervention and drug therapy

AF and PCI in Practice.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

European Society of Cardiology 2003

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Section D: Clinical trial update: GP IIb/IIIa inhibition

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

Randomized Comparison in the Setting of Acute MI

TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Role of Stenting in Acute MI: PAMI Stent Pilot Trial

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

European Heart Journal Advance Access

INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Presentation transcript:

Diagnosis of acute MI Pharmacologic therapy* Immediate angiography PTCAPTCA Other Rx *Antithrombin agents, antiplatelet agents, and fibrinolytic agents. “Prejunctive” Therapy A strategy to promote very early patency for some patients (drug responders) and very high final patency rates (assured by PTCA) for all patients

Plasminogen-Activator Angioplasty Compatibility Trial (PACT) Ross AM, et al. J Am Coll Cardiol. 1999;34: Eligible acute infarct patients n=606 ASA, IV heparin t-PA 50 mg bolus Placebo bolus Immediate angiography TIMI 3 TIMI 0, 1, 2 Second bolus of study drug Immediate angioplasty Follow-up angiogram 5-7 days, ETT 6 wk Randomize

*All comparisons P< Ross AM, et al. J Am Coll Cardiol. 1999;34: Patency of the Infarct Artery on Catheter Laboratory Arrival (Core Laboratory)

Adapted from Ross AM, et al. J Am Coll Cardiol. 1999;34: P=NS TIMI 2, 3 TIMI 3 TIMI 2TIMI 3 Technical Results of PTCA: Core Laboratory Results % of Patients

Adapted from Ross AM, et al. J Am Coll Cardiol. 1999;34: % Convalescent LVEF Convalescent LV Function By Patency Group: Global Ejection Fraction P=0.004

Adverse Eventt-PAPlaceboP Value Major bleeding12.9%13.5%0.84 Stroke (any)0.7% 0.99 Intracranial hemorrhage0.3% 0.99 Emergencyrevascularization7.3%7.2%0.98 Hospital death3.6%3.0% day death3.6%3.3%0.81 Adapted from Ross AM, et al. J Am Coll Cardiol. 1999;34: PACT: Adverse Events

Summary: Pharmacologic/Mechanical Combination Therapy Safe: no increase in ICH, CABG, reocclusion, or repeat PTCA Mounting evidence of better clinical outcomes May have special value in decreasing time delay to revascularization associated with PTCA Outcomes best if artery open before PTCA